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Juvenile Localized Scleroderma (JLS), is characterised by
presence of areas of skin thickening, which is relatively
benign, but if deeper tissues such as muscle and bone are
involved severe deformities may develop. Mycophenolate
Mofetil (MMF) is increasingly utilised both for treatment
of systemic sclerosis and immune-mediated skin diseases
such as psoriasis, graft-versus-host and lichen planus. Our
aim was to evaluate efficacy and safety of MMF in the
treatment of JLS. Seven patients entered the study (3 M, 4
F). The JLS clinical subtypes were Pansclerotic morphea (2
pts), Generalized Morphea (1), En coup de Sabre (ECDS)
(1), Mixed (ECDS/Linear) (3), The age at onset of the dis-
ease was 7.5 yrs (range 3 – 16.9) and the disease duration
at diagnosis was 1.9 years (range 3 months – 4 years). Pre-
vious treatments before starting MMF were oral steroids in
6 pts, IV steroids in 5, MTX in 5, while the patient with
ECDS received no treatment. MMF was started because of
steroids side effects in one patient and MTX resistance in
5. In ECDS MMF was chosen because of concomitant cer-
ebral vasculitis. All treated patients presented clinical
improvement which allowed withdrawal of steroids. Over
the follow-up of 27 months (range 6–36 months) only
mild abdominal discomfort in one patient was reported.
In conclusion MMF seems to be effective in severe or MTX-
refractory JLS and is generally well tolerated. Further con-
trolled studies are necessary to confirm these data.
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